Francis Knuettel II - 02 Jul 2025 Form 4/A - Amendment Insider Report for Pelthos Therapeutics Inc. (PTHS)

Role
CFO, Treas & Secty
Signature
/s/ Francis Knuettel II
Issuer symbol
PTHS
Transactions as of
02 Jul 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
01 Apr 2026, 17:39:34 UTC
Date Of Original Report
07 Jul 2025
Previous filing
03 Jul 2025
Next filing
06 Oct 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Francis Knuettel II filed Form 4/A - Amendment for Pelthos Therapeutics Inc. (PTHS) on 01 Apr 2026."

Quick Takeaways

  • This page summarizes Francis Knuettel II's Form 4/A - Amendment filing for Pelthos Therapeutics Inc. (PTHS).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 01 Apr 2026, 17:39.

What Changed

  • Previous filing in this sequence was filed on 03 Jul 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Francis Knuettel II CFO, Treas & Secty C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM /s/ Francis Knuettel II 01 Apr 2026 0001433316

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTHS Common Stock Award +33,472 $0.000000* 33,472 02 Jul 2025 Direct F1, F2
holding PTHS Common Stock 10,000 02 Jul 2025 By Camden Capital LLC F3
holding PTHS Common Stock 12,816 02 Jul 2025 By Lara Knuettel Revocable Trust F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.
F2 The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
F3 Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
F4 Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Remarks:

Exhibit 24 - Power of Attorney

Sponsored